middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
pulmonari
infect
mortal
spike
glycoprotein
merscov
key
target
vaccin
therapeut
mediat
viral
entri
membranefus
host
cell
four
differ
subunit
protein
receptorbind
domain
rbd
aa
aa
aa
aa
gener
use
baculovir
system
immun
mice
develop
neutral
antibodi
develop
hybridoma
select
five
neutral
mab
immun
merscov
strain
spseudotyp
lentiviru
howev
five
monoclon
antibodi
mab
neutral
pseudotyp
mutat
addit
one
mab
show
neutral
activ
pseudovirus
amino
acid
substitut
f
g
strain
f
g
mab
could
neutral
pseudotyp
mutat
three
neutral
mab
show
broad
neutral
activ
impli
mutat
residu
critic
gener
neutral
escap
variant
merscov
interestingli
five
neutral
mab
bind
affin
rbd
although
mab
gener
rbd
neutral
activ
addit
chimer
antibodi
human
fc
light
chain
show
neutral
effect
wild
type
merscov
similar
origin
mous
mab
thu
mab
util
identif
specif
mutat
merscov
korean
patient
isol
genom
identifi
possess
point
mutat
receptorbind
domain
rbd
glycoprotein
kim
et
al
b
min
et
al
specif
genom
show
mutat
rbd
show
g
mutat
exhibit
reduc
affin
rbd
cellular
receptor
human
dipeptidyl
peptidas
also
known
compar
wild
type
rbd
suggest
merscov
adapt
humantohuman
spread
may
driven
escap
neutral
antibodi
rather
evolv
stronger
affin
kim
et
al
park
et
al
therefor
sever
mab
differ
epitop
within
might
use
prophylact
therapeut
agent
avoid
immun
escap
viru
conform
rbd
fulllength
truncat
version
may
differ
recombin
rbd
subunit
protein
may
induc
neutral
antibodi
effici
larger
subunit
transmembran
delet
studi
produc
recombin
rbd
protein
insect
cell
use
baculoviru
induc
neutral
antibodi
mice
immun
subunit
protein
develop
mab
hybridoma
techniqu
sever
mab
select
character
neutral
activ
differ
merscov
spseudotyp
viru
wild
type
result
studi
expect
contribut
develop
diagnost
tool
merscov
mutat
well
mabbas
therapeut
hek
cell
atcc
manassa
va
usa
grown
co
dulbecco
modifi
eagl
medium
dmem
invitrogen
waltham
usa
supplement
fetal
bovin
serum
fb
gibco
waltham
usa
penicillin
streptomycin
invitrogen
spodoptera
frugiperda
cell
thermo
fisher
waltham
usa
cultur
ii
sfm
medium
gibco
penicillinstreptomycin
welgen
daegu
south
korea
nonhumidifi
nonco
incub
rpm
suspens
human
codonoptim
gene
encod
aa
merscov
isol
genbank
access
number
mammalian
codonoptim
strain
genbank
access
number
strain
genbank
access
number
synthes
genscript
nj
usa
clone
pcmvr
rao
et
al
use
sali
bamhi
site
mutat
gene
encod
substitut
residu
rbd
gener
sitedirect
mutagenesi
quikchang
ii
xl
sitedirect
mutagenesi
kit
agil
technolog
santa
clara
ca
usa
use
strain
gene
templat
sequenc
strain
mutat
merscov
rbd
residu
obtain
genbank
databas
tabl
insert
gene
recombin
plasmid
verifi
sequenc
cosmogenetech
seoul
korea
insect
cell
codonoptim
gene
strain
synthes
bioneer
daejeon
korea
use
pcr
templat
four
merscov
spike
subunit
gene
aa
aa
aa
rbd
aa
pcramplifi
primer
contain
bamhi
site
forward
primer
histag
sequenc
sali
site
revers
primer
rbd
signal
peptid
sequenc
also
includ
forward
primer
tabl
amino
acid
sequenc
merscov
spike
deriv
strain
goo
et
al
viru
research
follow
bamhi
site
pcr
product
clone
pfastbac
donor
vector
baculoviru
express
system
thermo
fisher
use
bamhi
sali
restrict
site
infecti
recombin
baculoviru
prepar
describ
previous
yang
et
al
recombin
protein
express
insect
cell
cell
ml
ml
infect
supernat
contain
recombin
baculoviru
cultur
three
day
rpm
cultur
media
collect
concentr
ammonium
sulfat
precipit
method
ammonium
sulfat
precipit
redissolv
buffer
solut
mm
trishcl
ph
nacl
mm
imidazol
histidinetag
protein
purifi
use
metal
affin
column
immobil
nickel
ligand
adar
biotech
rehovot
israel
purifi
protein
elut
column
elut
buffer
mm
trishcl
ph
nacl
mm
imidazol
subject
dialysi
mm
trishcl
buffer
ph
contain
glycerol
concentr
mgml
femal
balbc
mice
purchas
nara
biotech
korea
anim
experi
immun
collect
ascit
approv
iacuc
iacuc
protocol
number
atgen
atgen
respect
mice
immun
twice
interv
merscov
recombin
subunit
protein
rbd
combin
freund
complet
adjuv
sigma
st
loui
ca
usa
via
subcutan
j
goo
et
al
viru
research
rout
mice
sacrif
day
last
immun
splenocyt
fuse
mous
myeloma
cell
fo
ratio
presenc
roch
basel
switzerland
day
cultur
hypoxanthineaminopterinthymidin
medium
elisaposit
hybridoma
subject
limit
dilut
select
base
pseudoviru
neutral
result
largescal
mab
product
ascit
fluid
mice
inocul
hybridoma
collect
purifi
use
rprotein
agaros
resin
amicogen
jinju
korea
isotyp
classif
purifi
mab
perform
use
pierc
rapid
elisa
mous
mab
isotyp
kit
thermo
accord
manufactur
instruct
chimer
mab
produc
describ
previous
dang
et
al
briefli
rna
extract
hybridoma
cell
firststrand
cdna
produc
v
h
v
l
region
amplifi
use
primer
restrict
sfii
nhei
bglii
clone
express
vector
produc
chimer
igg
sequenc
primer
follow
chimer
antibodi
name
possess
human
fc
human
light
chain
chimer
antibodi
name
human
fc
human
kappa
light
chain
prepar
dna
plasmid
transient
transfect
hek
cell
invitrogen
use
polyethyleneimin
cell
cultur
supernat
freestyl
express
media
thermo
fisher
scientif
harvest
day
antibodi
purifi
use
polyprep
chromatographi
column
biorad
hercul
ca
usa
pack
protein
purifi
mg
mg
obtain
pseudoviru
neutral
activ
hybridoma
gener
use
splenocyt
mice
immun
rbd
recombin
protein
distribut
neutral
activ
hybridoma
merscov
spike
pseudotyp
lentiviru
hybridoma
cultur
supernat
incub
merscov
pseudovirion
min
ad
cell
incub
h
replac
fresh
medium
analyz
luciferasereport
activ
day
later
rel
luminesc
unit
rlu
convert
neutral
activ
b
neutral
activ
select
hybridoma
left
right
strain
pseudovirion
among
hybridoma
select
hybridoma
test
neutral
activ
indic
pseudovirion
four
tenfold
serial
dilut
hybridoma
cultur
supernat
use
pseudovirion
undilut
cultur
supernat
use
pseudovirion
c
bind
domain
select
mab
within
protein
seven
mab
purifi
bind
region
assess
use
elisa
valu
indic
od
coat
plate
subunit
antigen
goo
et
al
viru
research
lentiviru
base
merscov
spseudotyp
particl
gener
hek
cell
seed
dmem
without
antibiot
petri
dish
ratio
yield
confluenc
time
transfect
lentivir
pseudovirion
express
merscov
protein
produc
cotransfect
hek
cell
three
plasmid
phrcmvluc
pcmv
naldini
et
al
ng
pcmvr
encod
plasmid
use
lipofectamin
invitrogen
medium
replac
overnight
incub
supernat
contain
viral
pseudotyp
particl
harvest
h
transfect
filter
use
filter
syring
store
aliquot
kim
et
al
titrat
pseudoviru
perform
use
lentivirusassoci
elisa
kit
cell
biolab
san
diego
ca
usa
cell
plate
densiti
cellswel
plate
complet
dmem
fb
penicillin
fig
dosedepend
neutral
activ
purifi
mab
differ
merscov
spike
pseudotyp
virion
mab
dilut
ng
test
mab
incub
indic
merscov
spseudotyp
virion
min
ad
cell
incub
h
replac
fresh
medium
analyz
luciferasereport
activ
day
later
rlu
valu
convert
neutral
activ
data
repres
mean
standard
deviat
least
two
independ
experi
statist
signific
determin
oneway
anova
follow
tukey
test
streptomycin
humidifi
atmospher
co
day
pseudovir
infect
confluenc
achiev
incub
merscov
spseudotyp
particl
serial
dilut
mous
immun
serum
neutral
antibodi
posit
control
sino
biolog
inc
beij
china
h
room
temperatur
mixtur
ad
cell
well
replac
fresh
media
h
incub
cell
lyse
h
lysi
buffer
promega
promega
madison
wi
usa
transfer
opaqu
plate
perkinelm
waltham
usa
kim
et
al
luciferas
activ
measur
ad
substrat
promega
use
spectramax
l
micropl
reader
molecular
devic
san
jose
ca
usa
yang
et
al
preincub
mab
ad
vero
cell
h
incub
cell
overlaid
medium
contain
seaplaqu
agaros
lonza
basel
switzerland
h
merscov
infect
cell
fix
fig
doserespons
curv
neutral
activ
mab
three
pseudovirus
merscov
rbd
identifi
korean
mer
outbreak
g
l
respect
mab
dilut
ng
test
mab
incub
indic
merscov
spseudotyp
virion
min
ad
cell
incub
h
replac
fresh
medium
analyz
luciferasereport
activ
day
later
rlu
valu
convert
neutral
activ
data
repres
mean
standard
deviat
least
two
independ
experi
statist
signific
determin
oneway
anova
follow
tukey
test
j
goo
et
al
viru
research
stain
antimerscov
n
protein
antibodi
sino
biolog
inc
count
viral
plaqu
rbd
antibodi
hybridoma
cultur
supernat
measur
elisa
describ
previous
shere
et
al
analys
perform
use
prism
graphpad
san
diego
ca
excel
program
microsoft
offic
differ
group
analyz
oneway
analysi
varianc
anova
follow
tukey
test
p
valu
consid
statist
signific
develop
neutral
mab
differ
epitop
sever
subunit
protein
design
antigen
merscov
glycoprotein
consist
globular
domain
ntermin
region
contain
rbd
respons
bind
host
cellular
receptor
follow
membraneproxim
domain
transmembran
domain
du
et
al
fig
recombin
protein
aa
aa
aa
rbd
aa
correspond
amino
acid
sequenc
merscov
strain
produc
insect
cell
use
baculoviru
express
system
fig
protein
immun
balbc
mice
hybridoma
fusion
perform
use
spleen
cell
cultur
supernat
hybridoma
cell
subject
elisa
assess
whether
secret
antibodi
bind
subunit
protein
data
shown
total
hybridoma
secret
antibodi
bind
subunit
protein
rbd
mab
merscov
spseudotyp
lentiviru
produc
evalu
neutral
activ
antibodi
secret
hybridoma
cell
pseudoviru
express
merscov
spike
protein
gener
cotransfect
plasmid
gagpol
luciferaseexpress
hek
cell
use
gene
without
endoplasm
reticulum
signal
kim
et
al
gene
england
strain
clone
tabl
rbd
gene
natur
occur
strain
merscov
clone
base
strain
gene
except
rbd
region
tabl
next
neutral
activ
panel
elisaposit
hybridoma
evalu
merscov
strain
spseudotyp
virion
inhibit
pseudoviru
infect
antibodi
quantifi
luciferas
activ
pseudovirusinfect
cell
fig
select
clone
test
spseudotyp
strain
fig
seven
clone
select
six
clone
one
clone
gener
immun
respect
among
clone
neutral
strain
inhibit
entri
pseudotyp
strain
target
cell
approxim
activ
seven
clone
subclon
final
mab
purifi
character
igg
subclass
light
chain
type
tabl
upon
examin
bind
domain
mab
bound
nonrbd
neutral
fclight
chainhuman
chimer
left
right
mab
purifi
f
cell
cultur
supernat
transfect
relev
dna
plasmid
run
sdspage
follow
coomassieblu
stain
reduc
condit
nr
nonreduc
condit
b
left
right
mab
dilut
ng
neutral
f
g
g
l
pseudotyp
virion
luciferas
activ
pseudoviru
convert
neutral
activ
c
neutral
activ
mous
chimer
wild
type
merscov
strain
assess
prnt
mab
dilut
ng
test
data
repres
least
two
independ
experi
mab
show
affin
rbd
fig
taken
togeth
sever
neutral
mab
gener
immun
although
antibodi
develop
rbd
immun
induc
neutral
effect
experiment
condit
fig
evalu
whether
mab
crossprotect
capabl
variou
merscov
strain
examin
neutral
activ
merscov
pseudoviru
gene
contain
differ
rbd
region
englandqatar
f
f
g
p
v
v
h
kor
g
l
strain
tabl
variant
exhibit
neutral
resist
mab
data
shown
among
five
mab
could
bind
rbd
three
mab
show
broad
neutral
activ
differ
spseudotyp
virus
fig
howev
mab
neutral
three
pseudovirus
possess
amino
acid
substitut
f
g
rbd
gene
englandqatar
strain
base
emc
gene
impli
residu
mutat
emc
elicit
neutral
escap
fig
mab
neutral
rbd
pseudotyp
fig
expect
bound
nonrbd
region
show
neutral
activ
even
highest
antibodi
dose
ng
mab
show
bind
affin
show
partial
neutral
effect
compar
rbdbind
neutral
mab
fig
make
mab
avail
human
clinic
use
standard
human
sampl
analysi
genet
engin
increas
similar
antibodi
variant
produc
natur
human
fc
region
replac
human
fc
light
chain
replac
human
chain
tabl
human
antibodi
produc
use
f
cell
transfect
clone
antibodi
dna
plasmid
purifi
protein
column
fig
chimer
mab
neutral
pseudovirus
korknih
l
variant
howev
show
lower
neutral
activ
pseudotyp
g
g
especi
f
variant
neutral
pseudotyp
variant
fig
also
observ
mous
mab
respect
neutral
activ
mous
chimer
mab
verifi
prnt
assay
wild
type
merscov
strain
fig
control
includ
prnt
neutral
neutral
wild
type
strain
dosedepend
manner
previou
pseudoviru
neutral
collect
chimer
mab
show
similar
neutral
effect
origin
mous
mab
respect
suggest
chimer
mab
use
distinguish
mutat
specif
residu
merscov
clinic
isol
studi
aim
develop
mab
specif
merscov
util
therapeut
diagnost
tool
variant
merscov
strain
merscov
singl
posit
strand
rna
viru
approxim
kb
encod
four
major
viral
structur
protein
includ
envelop
membran
nucleocapsid
well
sever
accessori
protein
sinc
merscov
mediat
viral
attach
fusion
human
cell
via
human
cellular
receptor
also
known
consid
target
mab
develop
includ
neutral
antibodi
gener
mab
mous
hybridoma
techniqu
use
recombin
subunit
protein
antigen
select
mab
hybridoma
base
specif
bind
abil
subunit
character
neutral
activ
divers
merscov
pseudovirus
six
mab
develop
show
specif
bind
affin
nonrbd
rbd
one
mab
produc
subunit
protein
immun
polyclon
serum
develop
show
high
neutral
activ
emc
pseudovirion
compar
immun
data
shown
howev
fail
obtain
potent
neutral
mab
mice
experiment
condit
rbdspecif
mab
show
higher
neutral
potenc
nonrbdbind
mab
nonrbd
consist
fact
report
neutral
mab
rbdspecif
pascal
et
al
wang
et
al
ying
et
al
mab
develop
group
also
bind
rbd
potent
neutral
merscov
de
wit
et
al
pascal
et
al
wang
et
al
ying
et
al
meanwhil
also
report
nonrbd
mab
mab
neutral
merscov
chen
et
al
pallesen
et
al
wang
et
al
zhang
et
al
studi
rbd
subunit
protein
could
induc
suffici
neutral
activ
unlik
protein
suggest
design
antigen
possess
appropri
structur
conform
crucial
develop
vaccin
therapeut
neutral
antibodi
baculovir
express
system
produc
recombin
subunit
protein
studi
henc
baculovirusexpress
consid
promis
merscov
vaccin
antigen
given
abil
induc
potent
neutral
antibodi
although
trimer
tag
prefus
conform
pallesen
et
al
may
differ
glycosyl
pattern
compar
mammalianexpress
protein
li
et
al
mab
target
rbd
show
high
crossneutr
activ
differ
merscov
pseudovirus
contrast
transduct
pseudovirion
chang
rbd
inhibit
mab
interestingli
two
mab
neutral
anoth
pseudovirion
specif
mutat
rbd
region
could
neutral
pseudovirion
chang
amino
acid
residu
particularli
site
g
meanwhil
neutral
pseudovirion
mutat
amino
acid
residu
compar
strain
sequenc
singl
amino
acid
chang
rbd
region
identifi
korea
outbreak
patient
report
mutat
either
g
reduc
viral
affin
human
cellular
receptor
kim
et
al
experi
lower
luciferas
activ
also
observ
target
cell
pseudoviru
infect
g
mutat
mab
develop
us
nih
possess
bind
affin
rbd
lost
neutral
effect
pseudovirion
mutat
amino
acid
residu
emc
strain
amino
acid
sequenc
common
amino
acid
influenc
loss
neutral
mab
residu
show
partial
neutral
activ
test
pseudovirus
nonrbd
hinder
cell
entri
entir
test
pseudovirus
structur
data
need
determin
precis
epitop
neutral
mab
mechan
combin
mab
might
delay
viral
escap
wild
type
merscov
strain
also
show
suscept
mab
regardless
origin
either
mous
fclight
chainhuman
chimer
antibodi
human
mab
may
util
calib
measur
human
immun
respons
therapeut
purpos
human
howev
symptom
often
appear
peak
viremia
combin
neutral
mab
therapi
would
use
onset
symptom
earli
enough
avoid
viremia
addit
mab
target
nonrbd
epitop
merscov
may
potenti
clinic
applic
prevent
andor
treatment
diseas
anim
model
reflect
human
merscov
infect
protect
effect
mab
may
better
assess
conclus
sever
mab
develop
murin
hybridoma
techniqu
may
util
merscov
diagnost
distinguish
escap
mutant
strain
combin
therapeut
antibodi
human
form
work
support
grant
ministri
health
welfar
republ
korea
